293 related articles for article (PubMed ID: 27372220)
1. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
[TBL] [Abstract][Full Text] [Related]
2. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
4. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
[TBL] [Abstract][Full Text] [Related]
5. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
6. Pharmacy-related theft of controlled substances: RxPATROL® findings.
Erensen JG; Haddox JD; Attre MS; Bauza LN
J Opioid Manag; 2018; 14(5):373-380. PubMed ID: 30387860
[TBL] [Abstract][Full Text] [Related]
7. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
8. Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study.
Cepeda MS; Fife D; Vo L; Mastrogiovanni G; Yuan Y
J Pain; 2013 Feb; 14(2):158-64. PubMed ID: 23253635
[TBL] [Abstract][Full Text] [Related]
9. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
10. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484
[TBL] [Abstract][Full Text] [Related]
11. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
Cheng HG; Coplan PM
Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
[TBL] [Abstract][Full Text] [Related]
12. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
[TBL] [Abstract][Full Text] [Related]
14. Assessing opioid shopping behaviour: a large cohort study from a medication dispensing database in the US.
Cepeda MS; Fife D; Chow W; Mastrogiovanni G; Henderson SC
Drug Saf; 2012 Apr; 35(4):325-34. PubMed ID: 22339505
[TBL] [Abstract][Full Text] [Related]
15. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
Sellers EM; Perrino PJ; Colucci SV; Harris SC
J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
[TBL] [Abstract][Full Text] [Related]
16. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
[TBL] [Abstract][Full Text] [Related]
17. Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries.
Ponté C; Lepelley M; Boucherie Q; Mallaret M; Lapeyre Mestre M; Pradel V; Micallef J
Drug Alcohol Depend; 2018 Jun; 187():88-94. PubMed ID: 29649695
[TBL] [Abstract][Full Text] [Related]
18. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
Sankey C; Setnik B; Harsanyi Z; Michalko K; Yang Z; Geoffroy P
J Opioid Manag; 2016; 12(2):149-59. PubMed ID: 27194200
[TBL] [Abstract][Full Text] [Related]
19. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
[TBL] [Abstract][Full Text] [Related]
20. Opioid shopping behavior: how often, how soon, which drugs, and what payment method.
Cepeda MS; Fife D; Chow W; Mastrogiovanni G; Henderson SC
J Clin Pharmacol; 2013 Jan; 53(1):112-7. PubMed ID: 23400751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
